To explore new combination prognostic biomarkers, we conducted this study in a cohort of NCT-treated BC patients and investigated the prognostic implications for both DFS and OS of immune biomarkers in peripheral blood, such as NLR, and at the tumor level (TILs), together with genomic proliferation markers (AURKA, MYBL2, and MKI67) and conventional parameters, and response to NCT. The gene discussed is AURKA; the disease is neoplasm.